Navigation Links
Charles Lafitte Foundation Pledges $1 Million to the American Cancer Society's Hope Lodge
Date:2/19/2008

BRIELLE, N.J., Feb. 19 /PRNewswire-USNewswire/ -- The Charles Lafitte Foundation (http://www.charleslafitte.org), a philanthropic organization committed to providing support for education, children's advocacy, medical research and issues and the arts, today announced that it has pledged $1 million to the American Cancer Society's Manhattan Hope Lodge, which will provide free, temporary housing for cancer patients who are undergoing treatment at facilities in New York.

"The Hope Lodge facilities play a vital role in helping cancer patients and their caregivers deal with the emotional and financial burdens that are associated with a cancer diagnosis," said Suzanne Citron, Co-Founder of The Charles Lafitte Foundation. "Our foundation exists to help better the lives of others and we are confident that our gift will enable the American Cancer Society to continue to provide housing and services to more patients and their families who must frequently travel distances for necessary cancer treatments."

The American Cancer Society has created nearly thirty Hope Lodge facilities across the United States, offering patients much more than a place to stay while undergoing cancer treatments. The Manhattan Hope Lodge, located at West 32nd Street, is currently receiving guests and will offer the warmth and security of home as well as educational services for patients and caregivers and a 24-hour toll-free call center and web site with comprehensive on-site libraries, providing families with the information to help them make informed medical decisions. The facility will also serve as a community center for patient support groups and cancer initiatives. The Charles Lafitte Foundation's donation will be provided in five yearly installments of $200,000 per year.

"Both Suzanne and I were immediately attracted to the American Cancer Society's Hope Lodge because not only do the facilities fulfill an immed
'/>"/>

SOURCE Charles Lafitte Foundation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Charles A. Peck, M.D., F.A.C.P. Joins LifeMasters as New Medical Director Focused on Client Experience
2. Ocular Pharma Company Charlesson Announces $2.35MM in New Funding
3. Charles S. Cohen, Pacific Design Center Augment Their Support for AIDS Walk Los Angeles
4. Charles Alan Launches Healthcare-focused Furniture Lines with NuBax Seating Technology, Offering Smart Design and Health Benefits
5. Groups Call On Senator Charles Schumer to Lead Senate In Strengthening Medicare
6. MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP
7. Charles River Laboratories International Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU
8. Fourth Annual James E. Marshall OCD Foundation Beyond Beauty Dinner to Honor E. Scott Beattie, Chairman and CEO, Elizabeth Arden, Inc. and Charles H. Townsend, President and CEO, Conde Nast Publications
9. National Patient Safety Foundation Partners with Vocera Communications
10. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
11. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...has got the approval of US Food and Drug Administr...ation (ANDA) for Meloxicam tablets used in the tre... // The approval is for Meloxicam tablets of stre... the company informed the Bombay Stock Exchange. "...
... injection users in US and South Africa practice u...g to a new study. // "Forty percent of the HIV-pos...risk male partners, and more than half of the time... said lead author Dr. Mary H. Latka. The study is ...
...children are to be weighed, measured and interview...ned to tackle //the growing menace of childhood ob...about 25 percent of the children aged between 7 an... This problem is increasing the incidence of heart...
...ation confirmed the 42nd human bird flu death in I... the two worst-hit by the virus,//a senior officia...day. "The result was positive, we received from t... today," Hariadi Wibisono, the director at the min...
Other Medicine News:
(Date:8/26/2008)...IANAPOLIS, Aug. 26 /- Semafore Pharma...national Congress on Targeted Therapies,in Cancer ...ovel,multi-targeted kinase inhibitors that demonst...l studies., A novel and proprietary molecular sca...ing allowing for the design of pan-PI3 kinase inhi...
(Date:8/26/2008)...T WORTH, Texas, Aug. 26 /- Healthpoin... trial to evaluate the effectiveness of a,widely p...aneous wounds and,resulting scars. The pilot study... reduced incidence of hypertrophic scars and benef...se SANTYL(R) Ointment.(1,2), "Given the findings ...
(Date:8/26/2008)...LO PARK, Calif., Aug. 26 /-... the positive one-year follow-up data,from the CUS...e of the,peer-reviewed journal, EuroIntervention. ...tella, M.D., of University Medical Center Utrecht,...II Investigators from 13 clinical,sites across Eur...
(Date:8/26/2008)...TTLE, Aug. 26 /- Omeros Corporation t... a Phase 1/Phase 2 trial investigating,OMS103HP in...onstruction,surgery. OMS103HP is an investigationa...ation solution and is designed to improve postoper...ve pain and allow patients an,earlier return to wo...
Breaking Medicine Technology:Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery 2New technology enhances therapeutic potential of cord blood stem cells 3551 1New technology enhances therapeutic potential of cord blood stem cells 3551 2DURECT Corporation to Participate in Upcoming Healthcare Conferences 5853 1Walking Golf Course Affects Swing Performance 21249 1Walking Golf Course Affects Swing Performance 21249 2US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 1US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 2US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 3US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 4US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 5
...he Intramuscular Formulation,of Peramivir Supports...za, BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-Fi...ed results from two Phase I,clinical studies of an...the Options for the Control of Influenza Conferenc...ional influenza,conference is held only once every...
...PRNewswire-FirstCall/ --,Genaera Corporation today...quemine (MSI-1436), its novel anti-obesity compoun...67th Scientific,Sessions, June 22 to 25 in Chicago...ine is a Multiple,Pathway Inhibitor that Causes Di...roves Plasma Insulin and Leptin Levels." , The pos...
Other Medicine Technology:BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 2BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 3BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 4BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 5BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 6Genaera to Present Preclinical Data on Trodusquemine for the,Treatment of Obesity at the American Diabetes Association 67th,Scientific Sessions 2Genaera to Present Preclinical Data on Trodusquemine for the,Treatment of Obesity at the American Diabetes Association 67th,Scientific Sessions 3Genaera to Present Preclinical Data on Trodusquemine for the,Treatment of Obesity at the American Diabetes Association 67th,Scientific Sessions 4
...ld, point-of-care device for the qualitative detec...The TOX/See device can detect up to nine of the mo...uires only a few drops of urine. Each TOX/See cass...nce and ease of use. TOX/See features integrated t...
...ld, point-of-care device for the qualitative detec...The TOX/See device can detect up to nine of the mo...uires only a few drops of urine. Each TOX/See cass...nce and ease of use. TOX/See features integrated t...
...ld, point-of-care device for the qualitative detec...The TOX/See device can detect up to nine of the mo...uires only a few drops of urine. Each TOX/See cass...nce and ease of use. TOX/See features integrated t...
...ld, point-of-care device for the qualitative detec...The TOX/See device can detect up to nine of the mo...uires only a few drops of urine. Each TOX/See cass...nce and ease of use. TOX/See features integrated t...
Medicine Products: